 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Tyvyt (sintilimab) / Eli Lilly
Enrollment change, Trial completion date, Trial withdrawal, Combination therapy, Metastases: IBI397 or Combination Therapies in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 5, 2023
P1a/1b, N=0, Withdrawn, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
N=30 --> 0 | Trial completion date: Dec 2023 --> Aug 2023 | Recruiting --> Withdrawn
- | AL008 / Alector
Journal, PD(L)-1 Biomarker: AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPĪ± Signaling and Activating Fc Receptors. (Pubmed Central) - Dec 9, 2022
AL008 also significantly potentiated the effects of T cell checkpoint blockade with anti-programmed death ligand-1 in syngeneic tumor models. This dual and specific mechanism of AL008, to our knowledge, provides a novel therapeutic strategy for targeting myeloid cells for immune activation.
- || Tyvyt (sintilimab) / Eli Lilly
Enrollment open, Combination therapy, Metastases: IBI397 or Combination Therapies in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 19, 2022
P1a/1b, N=30, Recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This dual and specific mechanism of AL008, to our knowledge, provides a novel therapeutic strategy for targeting myeloid cells for immune activation. Not yet recruiting --> Recruiting
- || Tyvyt (sintilimab) / Eli Lilly
New P1 trial, Combination therapy, Metastases: IBI397 or Combination Therapies in Patients With Advanced Malignancies (clinicaltrials.gov) - Feb 17, 2022
P1a/1b, N=30, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.